---
layout: default
title: Umeclidinium
parent: AI Predictions (L5)
nav_order: 626
evidence_level: L5
indication_count: 10
---

# Umeclidinium
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Umeclidinium: From COPD to Migraine Disorder

## One-Sentence Summary

Umeclidinium is a long-acting muscarinic antagonist (LAMA) used clinically as a bronchodilator in chronic obstructive pulmonary disease (COPD). The TxGNN model predicts it may be effective for **Migraine Disorder** (score 96.36%), but this prediction is currently supported by **no clinical trials and no literature** — it is a topological model prediction only, and the evidence pack itself flags the underlying anticholinergic mechanism as having no known link to migraine pathophysiology.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Chronic Obstructive Pulmonary Disease (COPD) — bronchodilation (drug class information from the evidence pack; no Taiwan/EU regulatory license record confirms this) |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 96.36% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism of action data for umeclidinium is not available in this evidence pack (flagged as a High-severity data gap). Based on the drug-class information that is available, umeclidinium is a long-acting muscarinic (anticholinergic) receptor antagonist (LAMA), used clinically for bronchodilation in COPD by blocking acetylcholine-mediated smooth muscle contraction in the airways.

Migraine pathophysiology is driven primarily by activation of the trigeminovascular system and the CGRP signaling pathway — neither of which has an established mechanistic connection to muscarinic receptor blockade. The evidence pack explicitly notes that this rationale is mechanistically weak and reflects only a knowledge-graph embedding similarity identified by TxGNN, not a plausible pharmacological pathway.

It is also worth noting that among the other top-ranked candidates for this drug, two (open-angle glaucoma, primary hereditary glaucoma) represent the **opposite** mechanistic direction: anticholinergic agents are a known relative risk factor in glaucoma populations rather than a treatment option, and should be treated as a safety signal rather than a repurposing opportunity. This reinforces that the current prediction set for umeclidinium should be interpreted cautiously rather than as validated therapeutic leads.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## EU Market Information

No marketing authorizations were found in the evidence pack. According to `taiwan_regulatory.market_status`, umeclidinium is currently **not marketed** in the EU under this dataset (0 authorizations recorded).

## Safety Considerations

Please refer to the SmPC for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
- The migraine indication is supported only by a model-level topological prediction (L5), with no clinical trials or literature, and the proposed mechanism (muscarinic antagonism) has no established link to migraine pathophysiology.
- Critical safety inputs (TFDA label warnings/contraindications) and detailed MOA data are both flagged as unresolved data gaps, one of which is Blocking severity — this alone prevents progression to the S1 safety-screening stage.
- Other top-ranked predictions for this drug (open-angle glaucoma, primary hereditary glaucoma) point in a mechanistically opposite direction and should be treated as a safety caution rather than an opportunity, further supporting a conservative Hold across this candidate line.

**To proceed, the following is needed:**
- TFDA label warnings and contraindications (DG001, Blocking) — required before any S1 safety evaluation
- Detailed mechanism of action data from DrugBank (DG002, High) — required to assess mechanistic plausibility
- Independent literature or preclinical evidence directly linking umeclidinium (not just the anticholinergic class) to migraine pathophysiology
- If any candidate advances, an explicit safety review addressing anticholinergic contraindications (e.g., angle-closure glaucoma risk) before further development
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

